Insights Into Multiple Myeloma
Perspectives on current treatment practices regarding frontline therapy of multiple myeloma (MM), the evolving role of MRD testing in MM, current treatment practices in later lines of therapy, and attitudes toward recently introduced agents
Meeting Moderator
Sushil Bhardwaj, MD
Good Samaritan Hospital Suffern, NY, USA
Look Inside This Report
Download a sample of this report and start discovering the insights
Report Snapshot
Insights on the following therapies were obtained
- bortezomib
- carfilzomib
- ixazomib
- elotuzumab
- daratumumab
- lenalidomide
- pomalidomide
- thalidomide
- melphalan
- cyclophosphamide
- bendamustine
- panobinostat
- selinexor
- isatuximab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A moderated roundtable discussion focusing on treatment of MM was held on October 26, 2019, in Seattle, WA, US
- Disease state and data presentations were developed in conjunction with a medical expert from University of Washington/Fred Hutch/Seattle Cancer Care Alliance
- The group of advisors comprised 9 community oncologists from the Northwest, US
- Data collection was accomplished through use of audience response system questioning and moderated discussion
